Evidence map›Paper›PMID 42150757›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2026

Long-Acting Injectable Cabotegravir HIV PrEP Uptake, Adherence, and Persistence in Two Large US Integrated Healthcare Systems.

Michael W Traeger, Wendy A Leyden, Lindsay G Eberhart, Jonathan E Volk, Michael J Silverberg, Michael A Horberg, Teaniese L Davis, Kenneth H Mayer, Douglas S Krakower, Jessica G Young and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Michael W TraegerDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA.ORCID 0000-0002-3452-350
Wendy A LeydenDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA.
Lindsay G EberhartKaiser Permanente Mid-Atlantic States, Mid-Atlantic Permanente Medical Group, Washington, DC.
Jonathan E VolkDepartment of Infectious Diseases, Kaiser Permanente San Francisco, San Francisco, CA.
Michael J SilverbergDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA.
Michael A HorbergKaiser Permanente Mid-Atlantic States, Mid-Atlantic Permanente Medical Group, Washington, DC.
Teaniese L DavisCentre for Research and Evaluation, Kaiser Permanente Georgia, Atlanta, GA.
Kenneth H MayerThe Fenway Institute, Fenway Health, Boston, MA.
Douglas S KrakowerDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA.
Jessica G YoungDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA.
Samuel M JennessDepartment of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA.
Julia L MarcusDepartment of Population Medicine, Harvard Pilgrim Health Care Institute, Boston, MA.

Funding

Cabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)R01AI174862 · NIAID · HARVARD PILGRIM HEALTH CARE, INC. · PI MARCUS, JULIA L. · 2022 to 2025
$3.3M
NIAID NIH HHS R01 AI174862NIH HHS AI174862
6 · The paper itself

Abstract

backgroundLong-acting cabotegravir (CAB-LA) was approved as HIV preexposure prophylaxis (PrEP) in the United States in December 2021, but data are limited on uptake, adherence, and persistence in clinical practice.

methodsWe extracted electronic health records of adults receiving oral or injectable PrEP during December 2021 to June 2024 at Kaiser Permanente (KP) Northern California and Mid-Atlantic States, 2 large integrated healthcare systems. We used χ 2 tests to compare characteristics of CAB-LA users and oral-PrEP-only users. Among CAB-LA users, we assessed adherence to bimonthly injections after lead-in doses (weeks 0 and 4) and used Kaplan-Meier methods to estimate persistence.

resultsAmong 23,311 individuals accessing oral or injectable PrEP, 180 (0.8%) received CAB-LA, with 23.9% having no documentation of previous PrEP use at KP. Compared with oral-PrEP-only users, a lower proportion of CAB-LA users were commercially insured (82.2% vs 89.2%; P = 0.014) and a higher proportion were Black (18.9% vs 10.2%) or Hispanic (34.4% vs 23.6%; P < 0.001 across race/ethnicity categories). Of 688 non-lead-in CAB-LA injections, 90.4% were administered within 8 weeks +7 days after the previous injection. Persistence on CAB-LA was 87.9% and 74.9% at 6 and 12 months, respectively. There were no incident HIV infections during CAB-LA use.

conclusionsCAB-LA is engaging new users, including populations traditionally underrepresented in PrEP uptake, and adherence and persistence are high in clinical practice. However, uptake of CAB-LA is extremely low, suggesting population affect will be limited without efforts to expand implementation and use.

Indexed as

Anti-HIV AgentsHIV InfectionsPre-Exposure ProphylaxisPyridonesAdministration, OralAdultCaliforniaDelivery of Health Care, IntegratedDiketopiperazinesFemaleHumansInjectionsMaleMiddle AgedUnited StatesAnti-HIV AgentscabotegravirDiketopiperazinesPyridonescabotegravirHIVlong-actingpre-exposure prophylaxisPrEP

Identifiers

PMID42150757
PMCPMC13372358

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.